Actuality: Bladder dysfunction in the elderly is a huge public health problem. Laboratory studies using animal models have so far not yielded new clinically useful information. The potential for an elderly patient to have a number of concomitant diseases means that a thorough characterization of his general condition is required before deciding on the most appropriate treatment option for urinary tract pathology. Therefore, more and more scientists, doctors and researchers are puzzled by the search for new means to protect urological health and improve the quality of life of the elderly, the search for so-called cytoprotectors of the bladder. IPH VGA peptide complexes are the latest developments in the protection of cells and tissues. The lack of building materials that peptides can provide has a negative effect on urological health, the level of oncoprotection and immunity decreases, which leads to the development of various diseases. Purpose: to study the possibilities of the IPH VGA peptide complex. Materials and methods: We have studied the effects of the IPH VGA peptide. We used German peptides IPH VGA, which have all the approvals and permits for the world markets, such as: WADA certificate (anti-doping), MAFFA certificate (safety), ORGANIC certificate, HALAL certificate, patent protection: patent in the United States - Patent Application Publicatin (United States, No.:US2021/052534A1, date: Feb.25,2021), patent in the European Union No. 016704471, patent in the Russian Federation No. 645608, patent in the People's Republic of China No. 30507522. The effectiveness of the use of the IPH VGA peptide was evaluated in the long term (for 1 year). Results: Recognition by the IPH VGA peptide of the gene apparatus provides protection against pathogens and controls the development of pathological changes in relation to the bladder. The IPH VGA peptide has a powerful oncoprotective and cytoprotective effect, as it is able to reduce the expression level of fibroblast growth factor by 81.8 ± 1.3%. The IPH VGA peptide has an anti-inflammatory cytoprotective effect against inflammatory diseases of the genitourinary system, in particular, the bladder. After the use of the IPH VGA peptide, the number of daytime urination decreased by 45.6 ± 1.2%, the degree of abdominal pressure by 33.5 ± 0.8%, the time to reach the maximum urination rate by 65.6 ± 1.3%, which indicates a high cytoprotective function of the VGA peptide with respect to bladder function.